Takeda Pharmaceutical (TKPHF) Tax Provisions (2017 - 2026)

Takeda Pharmaceutical's Tax Provisions history runs 10 years deep, the most recent figure standing at -$180.0 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 63.73% year-over-year to -$180.0 million; the TTM figure through Mar 2026 stood at -$2.4 billion (changed 0.3% YoY), while the FY2026 annual figure was $452.8 million, up 3.04% from the prior year.
• Tax Provisions was -$180.0 million for Q1 2026 at Takeda Pharmaceutical, up from -$290.5 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $84.9 million in Q4 2022 to a low of -$1.4 billion in Q3 2025.
• Historically, Tax Provisions has averaged -$476.8 million across 5 years, with a median of -$342.3 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Tax Provisions surged 167.15% in 2022, then slumped 986.37% in 2023.
• A 5-year view of Tax Provisions shows it stood at $84.9 million in 2022, then plunged by 503.15% to -$342.3 million in 2023, then increased by 14.11% to -$294.0 million in 2024, then gained by 1.21% to -$290.5 million in 2025, then surged by 38.04% to -$180.0 million in 2026.
• The last three Tax Provisions figures came in at -$180.0 million (Q1 2026), -$290.5 million (Q4 2025), and -$1.4 billion (Q3 2025), per Business Quant data.